Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director · Chief Operating Officer · 10% owner | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of LifeSci Investments, LLC | 1,701,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,701,000 F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 30, 2023 · Filed November 01, 2023
Section 16 reporting ended · disclosed 2023-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 347,085 |
Reported balance
After 2023-10-30 transaction · row 1
1 source rowRow 1 · 2023-10-30 · Sale · Disposed 72,603 · Balance 347,085 F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2018 Filed Sep 7, 2018 20:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,540 | $22.60 | $102,604.00 |
DisclosureSEC source: 0001437749-18-016715 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 20:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.26 | $15,800.40 |
DisclosureSEC source: 0001437749-18-016715 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 22:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 12,540 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-18-015780 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,247 Underlying: Common Stock · 12,540 shares Expires 2021-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 22:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,540 | $19.50 | $244,530.00 |
DisclosureSEC source: 0001437749-18-015780 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. (the "Registrant") on December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.85 to $20.10, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 22:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.12 | $14,044.80 |
DisclosureSEC source: 0001437749-18-015780 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 12,540 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-18-013390 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,787 Underlying: Common Stock · 12,540 shares Expires 2021-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,540 | $19.90 | $249,546.00 |
DisclosureSEC source: 0001437749-18-013390 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. (the "Registrant") on December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.76 to $20.01, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 22:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.12 | $14,044.80 |
DisclosureSEC source: 0001437749-18-013390 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 21, 2018 01:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 12,540 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-18-012166 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,327 Underlying: Common Stock · 12,540 shares Expires 2021-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 21, 2018 01:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,540 | $12.89 | $161,640.60 |
DisclosureSEC source: 0001437749-18-012166 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. on December 14, 2017. Read SEC document |
| June 18, 2018 Filed Jun 21, 2018 01:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.12 | $14,044.80 |
DisclosureSEC source: 0001437749-18-012166 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 16, 2018 23:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Options · Derivative | 12,540 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-18-010178 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,867 Underlying: Common Stock · 12,540 shares Expires 2021-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 16, 2018 23:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,540 | $8.65 | $108,471.00 |
DisclosureSEC source: 0001437749-18-010178 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. (the "Registrant") on December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.56 to $8.7203, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2018 Filed May 16, 2018 23:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.12 | $14,044.80 |
DisclosureSEC source: 0001437749-18-010178 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 20:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 5,900 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-18-007095 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,407 Underlying: Common Stock · 5,900 shares Expires 2021-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 20:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,900 | $7.22 | $42,598.00 |
DisclosureSEC source: 0001437749-18-007095 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. (the "Registrant") on December 14, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.02 to $7.34, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 17, 2018 Filed Apr 18, 2018 20:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 5,900 | $1.12 | $6,608.00 |
DisclosureSEC source: 0001437749-18-007095 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 6,640 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001437749-18-007095 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,307 Underlying: Common Stock · 6,640 shares Expires 2021-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 6,640 | $7.15 | $47,476.00 |
DisclosureSEC source: 0001437749-18-007095 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. (the "Registrant") on December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.30, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:22 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 6,640 | $1.12 | $7,436.80 |
DisclosureSEC source: 0001437749-18-007095 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 12,540 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001144204-18-015309 · tv488755_4.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,947 Underlying: Common Stock · 12,540 shares Expires 2021-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The reporting person exercised this option to purchase 12,540 shares on February 15, 2018. For more information regarding that option exercise, see the Form 4 filed by the reporting person on February 16, 2018. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,540 | $5.27 | $66,085.80 |
DisclosureSEC source: 0001144204-18-015309 · tv488755_4.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. (the "Registrant") on December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.28, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.12 | $14,044.80 |
DisclosureSEC source: 0001144204-18-015309 · tv488755_4.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 22:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantEmployee Stock Option · Derivative | 229,226 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001144204-18-013908 · tv488196_4.xml · derivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,226 Underlying: Common Stock · 229,226 shares Expires 2021-12-20 F1 · derivative.exercise_date: As disclosed in the registrants annual report on Form 10-K for the year ended December 31, 2016, on December 20, 2016, the reporting person was granted an option to purchase 229,226 shares of common stock. The option vests in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares will vest on March 8, 2019. No Form 4 filing was required upon the initial grant of the option because the option was subject to vesting based on conditions that were not tied to the passage of time and continued employment and not tied directly to the market price of the registrant's common stock. Read SEC document |
| February 15, 2018 Filed Feb 17, 2018 00:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,540 | $5.26 | $65,960.40 |
DisclosureSEC source: 0001144204-18-009619 · tv486421_4.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. (the "Registrant") on December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 15, 2018 Filed Feb 17, 2018 00:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.12 | $14,044.80 |
DisclosureSEC source: 0001144204-18-009619 · tv486421_4.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 23:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 12,540 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001144204-18-002502 · tv483516_4.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,027 Underlying: Common Stock · 12,540 shares Expires 2021-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 23:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,540 | $5.57 | $69,847.80 |
DisclosureSEC source: 0001144204-18-002502 · tv483516_4.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2017, the terms of which have been disclosed in a Form 8-K filed by BioLife Solutions, Inc. on December 14, 2017. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 23:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 12,540 | $1.12 | $14,044.80 |
DisclosureSEC source: 0001144204-18-002502 · tv483516_4.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 02:40 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-000678 · tv482657_4.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,517 F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. Read SEC document |
| February 07, 2017 Filed Feb 10, 2017 00:40 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001144204-17-007173 · v458958_4.xml · derivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2022-02-17 F1 · derivative.exercise_date: The options vest 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.